Baidu
map

Cell Host & Microbe :抗生素可能恶化哮喘症状

2014-01-17 佚名 生物360

日前,日本筑波大学的研究人员发现,服用抗生素会破坏实验鼠肠道的菌群平衡,从而使哮喘症状恶化。相关论文在线刊登在了近期的《细胞-宿主与微生物》Cell Host & Microbe杂志上。研究中,科学家让实验鼠吸入会导致过敏的物质,使其患上哮喘。结果显示,如果实验鼠预先服用了抗生素,其哮喘症状比未服用抗生素的实验鼠更严重,支气管内引发炎症的细胞数量相当于后者的约 2 倍。研究人员发现,在服用



日前,日本筑波大学的研究人员发现,服用抗生素会破坏实验鼠肠道的菌群平衡,从而使哮喘症状恶化。相关论文在线刊登在了近期的《细胞-宿主与微生物》Cell Host & Microbe杂志上。【原文下载

研究中,科学家让实验鼠吸入会导致过敏的物质,使其患上哮喘。结果显示,如果实验鼠预先服用了抗生素,其哮喘症状比未服用抗生素的实验鼠更严重,支气管内引发炎症的细胞数量相当于后者的约 2 倍。

研究人员发现,在服用了抗生素的实验鼠肠道内,一种有害的念珠菌数量增加,它们制造的物质会激活免疫细胞,引发支气管炎症等过敏反应。使用遏制念珠菌增殖和发挥致病作用的药物后,实验鼠的哮喘症状减轻了。

该成果可能促进开发出治疗哮喘的新药。

原文出处:

Yun-Gi Kim,Kankanam Gamage Sanath Udayanga,Naoya Totsuka,Jason B. Weinberg,Gabriel Núñez,Akira Shibuya. Gut Dysbiosis Promotes M2 Macrophage Polarization and Allergic Airway Inflammation via Fungi-Induced PGE2. Cell Host & Microbe, 15 January 2014【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1857316, encodeId=744f185e3168f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Apr 05 06:53:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868751, encodeId=240d1868e51dc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 11 23:53:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958992, encodeId=1cc4195899211, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 17 11:53:00 CST 2014, time=2014-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084095, encodeId=46be20840953d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Nov 17 12:53:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1857316, encodeId=744f185e3168f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Apr 05 06:53:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868751, encodeId=240d1868e51dc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 11 23:53:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958992, encodeId=1cc4195899211, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 17 11:53:00 CST 2014, time=2014-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084095, encodeId=46be20840953d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Nov 17 12:53:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1857316, encodeId=744f185e3168f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Apr 05 06:53:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868751, encodeId=240d1868e51dc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 11 23:53:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958992, encodeId=1cc4195899211, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 17 11:53:00 CST 2014, time=2014-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084095, encodeId=46be20840953d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Nov 17 12:53:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2014-03-17 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1857316, encodeId=744f185e3168f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Apr 05 06:53:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868751, encodeId=240d1868e51dc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 11 23:53:00 CST 2014, time=2014-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958992, encodeId=1cc4195899211, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 17 11:53:00 CST 2014, time=2014-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084095, encodeId=46be20840953d, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Nov 17 12:53:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2014-11-17 xjy02

相关资讯

PNAS:对抗超级细菌的新武器

在细菌与现代医学的军备竞赛中,细菌一直占据优势。近几十年来,细菌抗生素耐药形成速度快于新抗生素的生成速度,使得细菌感染越来越难于治疗。科学家们担心一种特别有毒力的、致死性“超级细菌”有可能在某天加入到现有的、无法医治的细菌行列中,导致类似黑死病一类的公共卫生大灾难。【原文下载】 现在,由以色列特拉维夫大学Sackler医学院临床微生物学与免疫学部Udi Qimron博士领导的一项新研究

Nature:一种能杀灭persister 休眠细胞的抗生素

细菌药物反应的双重性质使人们更加担心今天的抗生素应对未来感染的能力。 一些细菌会形成遗传抗性,而其他的则会通过形成被称为 “persister”的休眠细胞(在这种细胞中抗生素的酶目标是失活的)而变得具有耐受性,能够在抗生素存在下存活。 Kim Lewis及同事进行了搜寻有可能通过破坏这些能量有限的细胞内的目标来杀灭persister 细胞的药物的研究工作。他们发现,acyldepsipepti

美药管局计划遏制养殖业使用抗生素

美国食品和药物管理局11日公布一份行业指导性文件,计划遏制养殖业使用具有“重要医学用途”的抗生素,从而最大限度地避免食用畜禽产品的人出现对抗生素的抗药性问题。 美国药管局当天发表声明说,世界各国都把抗生素抗药性视为重大公共卫生威胁,仅在必要的治疗时才使用抗生素非常重要。但长期以来,人们一直给牛、猪和家禽的饲料或饮用水中添加抗生素,以促进它们的生长,提高饲养效率。由于一些畜禽抗生素也是治疗

PLoS One :血凝块能吸收细菌毒素?

在脊椎动物和节肢动物中,血液凝结包括聚集的血小板血栓的形成(细胞凝块)和由凝块的结构蛋白聚合形成的细胞外纤维状凝块,即哺乳动物中的纤维蛋白、甲壳类动物中的血浆脂蛋白和马蹄蟹(Limulus polyphemus)中的凝固素。这些凝块的功能是止血,另外,细胞外凝块还通过提供一种消极的抗菌障碍和微生物截留装置,发挥先天免疫系统的作用,直接作用于皮肤的伤口部位。来自美国加利福尼亚大学(

Lancet :网络培训有助控制对急性呼吸道感染的抗生素处方率

在初级保健医疗场所中大量开具抗生素处方,是抗生素耐药性的主要原因。10月发表在Lancet的一项研究评估了在多个医疗保健系统中,是否可以通过基于互联网培训模式改变开处方习惯。结果表明,网络培训跨越了语言与文化界限,在降低呼吸道感染抗生素处方率方面起到了重要作用。 背景:在初级保健医疗中大量应用抗生素,是导致产生抗生素耐药性的主要原因。医生和患者的教育程度会降低处方率,但主要依赖于工作人员的训练有

研究揭示细菌在抗生素攻击下的保命伎俩

来自耶路撒冷希伯来大学的研究人员,第一次揭示出了某些细菌能够在抗菌治疗中存活下来的机制。他们的研究工作有可能为找到一些新的方法控制这些细菌铺平了道路。 已知一些细菌可通过突变来对抗生素产生耐药,除此之外,还存在另外一些 “持久存在的细菌”(persistent bacteria)类型,它们并没有抗生素抗性,而是在暴露于抗菌治疗时继续以一种休眠或失活状态存在。当治疗结束

Baidu
map
Baidu
map
Baidu
map